1,584 results on '"Mohr, Peter"'
Search Results
2. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma
3. BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
4. Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma
5. Hybrid-3D robotic suite in spine and trauma surgery - experiences in 210 patients
6. Total reaction cross section of light stable and exotic nuclei on lead at energies around the Coulomb barrier
7. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales.
8. Early versus late response to PD-1-based immunotherapy in metastatic melanoma
9. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
10. On the dimension of angles and their units
11. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
12. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
13. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
14. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
15. Predicting compliance: Leveraging chat data for supervised classification in experimental research
16. The Quantum Reform of the International System of Units
17. Tests of Fundamental Physics
18. Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
19. LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients
20. Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform
21. Portfolio Decisions and Brain Reactions via the CEAD method
22. Yrast band in the heavy $N = Z$ nucleus $^{88}$Ru: $\alpha$-cluster approach
23. Comment on 'Observation of annual modulation by $\gamma$ rays from ($\alpha$,$\gamma$) reactions at the Soudan Underground Laboratory'
24. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
25. Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
26. Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
27. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
28. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
29. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
30. Angles are inherently neither length ratios nor dimensionless
31. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
32. Cross sections at sub-Coulomb energies: full optical model vs.\ barrier transmission for $^{40}$Ca + $\alpha$
33. Direct capture cross section of $^{9}$Be(n,$\gamma$)$^{10}$Be
34. Characterisation and outcome of RAC1 mutated melanoma
35. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales
36. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023
37. Revised Cross Section of the $^{13}$C($\alpha$,n)$^{16}$O reaction between 5 and 8 MeV
38. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
39. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
40. Clinical determinants of long-term survival in metastatic uveal melanoma
41. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
42. $\alpha$-cluster states in $^{46,54}$Cr from double-folding potentials
43. Uncertainty of the astrophysical $^{17,18}$O($\alpha$,n)$^{20,21}$Ne reaction rates and the applicability of the statistical model for nuclei with $A \lesssim 20$
44. Adaptive User Perspective Rendering for Handheld Augmented Reality
45. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
46. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.
47. Development of a new real-time PCR for the detection of pilchard orthomyxovirus (POMV) in apparently healthy fish
48. Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits
49. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
50. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.